221 related articles for article (PubMed ID: 23716537)
61. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities.
Kuo TT; Shih LY; Tsang NM
Int J Surg Pathol; 2004 Oct; 12(4):375-87. PubMed ID: 15494863
[TBL] [Abstract][Full Text] [Related]
62. Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2018 Feb; 13(1):37-43. PubMed ID: 29396703
[TBL] [Abstract][Full Text] [Related]
63. The new biology of PTCL-NOS and AITL: current status and future clinical impact.
Timmins MA; Wagner SD; Ahearne MJ
Br J Haematol; 2020 Apr; 189(1):54-66. PubMed ID: 32064593
[TBL] [Abstract][Full Text] [Related]
64. Primary cutaneous follicular helper T-cell lymphoma.
Santonja C; Soto C; Manso R; Requena L; Piris MA; Rodríguez-Pinilla SM
J Cutan Pathol; 2016 Feb; 43(2):164-70. PubMed ID: 26282465
[TBL] [Abstract][Full Text] [Related]
65. Frequent expression of CD30 antigen in the primary gastric non-B, non-Hodgkin lymphomas.
Iwamizu-Watanabe S; Yamashita Y; Yatabe Y; Nakamura S; Mori N
Pathol Int; 2004 Jul; 54(7):503-9. PubMed ID: 15189504
[TBL] [Abstract][Full Text] [Related]
66. [Molecular mechanisms of angioimmunoblastic T-cell lymphoma].
Sakata-Yanagimoto M
Rinsho Ketsueki; 2015 Mar; 56(3):246-52. PubMed ID: 25876776
[TBL] [Abstract][Full Text] [Related]
67. Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas.
Haedicke W; Ho FC; Chott A; Moretta L; Rüdiger T; Ott G; Müller-Hermelink HK
Blood; 2000 Jun; 95(11):3628-30. PubMed ID: 10828054
[TBL] [Abstract][Full Text] [Related]
68. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
[TBL] [Abstract][Full Text] [Related]
69. Zebras and hen's teeth: recognition and management of rare T and NK lymphomas.
Mehta-Shah N; Horwitz S
Hematology Am Soc Hematol Educ Program; 2015; 2015():545-9. PubMed ID: 26637770
[TBL] [Abstract][Full Text] [Related]
70. CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland.
Forconi F; Bocchia M; Marconcini S; Bigazzi C; Milani M; Fraternali-Orcioni G; Lauria F
Haematologica; 1999 Oct; 84(10):946-8. PubMed ID: 10509044
[TBL] [Abstract][Full Text] [Related]
71. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30
Wang D; Zeng C; Xu B; Xu JH; Wang J; Jiang LJ; Wang QX; Li CR; Wang N; Huang L; Zhang YC; Xiao Y; Zhou JF
Blood Cancer J; 2020 Jan; 10(1):8. PubMed ID: 31974371
[No Abstract] [Full Text] [Related]
72. Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii.
Cheson BD; Horwitz SM; Weisenburger DD
Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 26):1-14; quiz 15-6. PubMed ID: 22362328
[TBL] [Abstract][Full Text] [Related]
73. Intestinal T-cell and natural killer-cell lymphomas in Taiwan with special emphasis on 2 distinct cellular types: natural killer-like cytotoxic T cell and true natural killer cell.
Tung CL; Hsieh PP; Chang JH; Chen RS; Chen YJ; Wang JS
Hum Pathol; 2008 Jul; 39(7):1018-25. PubMed ID: 18482744
[TBL] [Abstract][Full Text] [Related]
74. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.
Falini B; Pileri S; Pizzolo G; Dürkop H; Flenghi L; Stirpe F; Martelli MF; Stein H
Blood; 1995 Jan; 85(1):1-14. PubMed ID: 7803786
[No Abstract] [Full Text] [Related]
75. CD30-positive malignant lymphomas: time for a change of management?
Engert A
Haematologica; 2013 Aug; 98(8):1165-8. PubMed ID: 23904233
[No Abstract] [Full Text] [Related]
76. [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
Zheng YY; Chen G; Zhou XG; Zhang SH; Zhang YN
Zhonghua Bing Li Xue Za Zhi; 2009 Mar; 38(3):173-7. PubMed ID: 19575853
[TBL] [Abstract][Full Text] [Related]
77. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.
Huang Y; Moreau A; Dupuis J; Streubel B; Petit B; Le Gouill S; Martin-Garcia N; Copie-Bergman C; Gaillard F; Qubaja M; Fabiani B; Roncador G; Haioun C; Delfau-Larue MH; Marafioti T; Chott A; Gaulard P
Am J Surg Pathol; 2009 May; 33(5):682-90. PubMed ID: 19295409
[TBL] [Abstract][Full Text] [Related]
78. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
79. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma.
Jones D; Fletcher CD; Pulford K; Shahsafaei A; Dorfman DM
Blood; 1999 May; 93(10):3487-93. PubMed ID: 10233901
[TBL] [Abstract][Full Text] [Related]
80. Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas.
Li T; Zhang B; Ye Y; Yin H
Hum Pathol; 2006 Jan; 37(1):54-60. PubMed ID: 16360416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
